PDL1 / b7h3-bispecific binding antibody and use thereof

WO2026114314A1PCT designated stage Publication Date: 2026-06-04SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner: SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
Filing Date: 2025-11-27
Publication Date: 2026-06-04

Application Information

Patent Timeline

27 Nov 2025

Application

04 Jun 2026

Publication

WO2026114314A1

IPC: C07K16/28; A61P35/00; A61K39/00; A61K47/68; C07K16/46; A61K39/395

CPC: A61K39/00; A61K39/395; A61K47/68; A61P35/00; C07K16/28; C07K16/46

AI Tagging

Application Domain

Hybrid immunoglobulins Antibody ingredients

Technology Topics

Antiendomysial antibodies Bispecific antibody

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗

Similar Technology Patents

Get free access to AI patent search and analysis

Check patentability, review prior art and ask IP Agent with full patent context.

Smart Images

Figure CN2025138192_04062026_PF_FP_ABST

Patent Text Reader

Abstract

The present invention relates to a PDL1- and B7H3-bispecific antibody, a nucleic acid molecule encoding the bispecific antibody, and a preparation method for the bispecific antibody. The present invention also relates to the use of the bispecific antibody in tumor treatment.

Need to check novelty before this filing date? Find Prior Art